TY  - JOUR 
AU  - Stewart, Stefan
AU  - Seco-Meseguer, Enrique
AU  - Diago-Sempere, Elena
AU  - Marín-Candón, Alicia
AU  - Carmona, Montserrat
AU  - Estébanez, Miriam
AU  - López-Fernández, Luis A
AU  - Imaz-Iglesia, Iñaki
AU  - del Mar García Saiz, María
AU  - Laserna-Mendieta, Emilio J
AU  - Peiró, Ana M
AU  - Farré, Magí
AU  - Rodriguez-Jimenez, Consuelo
AU  - Saiz-Rodriguez, Miriam
AU  - Sanabria-Cabrera, Judith
AU  - Rosas-Alonso, Rocío
AU  - Abad-Santos, Francisco
AU  - Pedrosa, Lucia
AU  - Carcas, Antonio J
AU  - García García, Irene
AU  - Borobia, Alberto M
PY  - 2024
SN  - 2044-6055
UR  - https://hdl.handle.net/10259/11917
AB  - Introduction Genetic variations impact drug response, driving the need for personalised medicine through pre-emptive pharmacogenetic testing. However, the adoption of pre-emptive pharmacogenetic testing for commonly prescribed drugs, such as statins,...
LA  - eng
PB  - BMJ
KW  - Medicina personalizada
KW  - Precision medicine
KW  - Farmacogenómica
KW  - Pharmacogenomics
TI  - Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial
DO  - 10.1136/bmjopen-2024-089823
T2  - BMJ Open
VL  - 14
ER  -